BCM
TEVA icon

Boltwood Capital Management’s Teva Pharmaceuticals TEVA Stock Holding History

Boltwood Capital Management’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-18,326
Closed -$1.2M – 102
2015
Q4 		$1.2M Buy
18,326
+250
+1% +$15.4K 1.1% 31
2015
Q3 		$1.02M Sell
18,076
-300
-2% -$19.5K 1.09% 31
2015
Q2 		$1.09M Sell
18,376
-400
-2% -$24.7K 1.07% 31
2015
Q1 		$1.17M Sell
18,776
-750
-4% -$43.6K 0.34% 53
2014
Q4 		$1.12M Buy
19,526
+150
+0.8% +$8.36K 0.32% 53
2014
Q3 		$1.04M Buy
19,376
+3,267
+20% +$173K 0.31% 55
2014
Q2 		$844K Buy
16,109
+600
+4% +$30.7K 0.25% 61
2014
Q1 		$819K Sell
15,509
-350
-2% -$16.2K 0.26% 57
2013
Q4 		$636K Buy
15,859
+316
+2% +$12.4K 0.21% 60
2013
Q3 		$587K Buy
15,543
+400
+3% +$15.6K 0.21% 59
2013
Q2 		$594K Buy
+15,143
New +$590K 0.24% 58

Other funds holding TEVA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
Lazard Asset Management
Lazard Asset Management New York $60.8B AUM 22.47% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Boltwood Capital Management's TEVA Position: Q1 2016 in Review

Boltwood Capital Management sold out of Teva Pharmaceuticals (TEVA) in Q1 2016, closing a stake of 18,326 shares — an estimated $1.2M sold.

Boltwood Capital Management first reported a position in TEVA in Q2 2013 and held it in 11 quarters. The position peaked at $1.2M in Q4 2015. 836 funds tracked by Wall St. Rank hold TEVA as of Q1 2016.

  • Boltwood Capital Management reported no remaining Teva Pharmaceuticals position as of Q1 2016 after selling out during the quarter.
  • Boltwood Capital Management sold 18,326 Teva Pharmaceuticals shares in Q1 2016, an estimated $1.2M.
  • Boltwood Capital Management first reported a position in Teva Pharmaceuticals in Q2 2013 and held it in 11 quarters.
  • Boltwood Capital Management's Teva Pharmaceuticals position peaked at $1.2M in Q4 2015.
  • 836 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2016.

Based on Boltwood Capital Management's 13F filing for Q1 2016, filed 14 Apr 2016.